MX366353B - Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders. - Google Patents

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders.

Info

Publication number
MX366353B
MX366353B MX2015018040A MX2015018040A MX366353B MX 366353 B MX366353 B MX 366353B MX 2015018040 A MX2015018040 A MX 2015018040A MX 2015018040 A MX2015018040 A MX 2015018040A MX 366353 B MX366353 B MX 366353B
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
movement disorders
hyperkinetic movement
therapeutic agents
Prior art date
Application number
MX2015018040A
Other languages
Spanish (es)
Other versions
MX2015018040A (en
Inventor
GAVALDÁ BATALLA Núria
Insa Boronat Raúl
Reig Bolaño Núria
Original Assignee
Som Innovation Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366353(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech S L filed Critical Som Innovation Biotech S L
Publication of MX2015018040A publication Critical patent/MX2015018040A/en
Publication of MX366353B publication Critical patent/MX366353B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de (RS)-[2-(3,4-dimetoxife nil)etil] [2-hidroxi-3-(3-metilfenoxi) propil]amina que tienen la fórmula (IA) o una sal farmacéuticamente aceptable del mismo para la formulación de una composición farmacéutica, útil para la profilaxis y/o el tratamiento de trastornos de movimiento hipercinéticos asociados con enfermedad de Huntington, enfermedad de Wilson, síndrome de Touret, síndrome de piernas inquietas, y disquinesia tardía.The present invention relates to the use of (RS) - [2- (3,4-dimethoxyphenyl) ethyl] [2-hydroxy-3- (3-methylphenoxy) propyl] amine having the formula (IA) or a salt pharmaceutically acceptable thereof for the formulation of a pharmaceutical composition, useful for the prophylaxis and / or treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Touret's syndrome, restless leg syndrome, and tardive dyskinesia.

MX2015018040A 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders. MX366353B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
MX2015018040A MX2015018040A (en) 2016-08-03
MX366353B true MX366353B (en) 2019-07-05

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015018040A MX366353B (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders.

Country Status (18)

Country Link
US (2) US9789072B2 (en)
EP (1) EP3010543B1 (en)
JP (1) JP6476174B2 (en)
KR (1) KR102254542B1 (en)
CN (1) CN105658238B (en)
AU (1) AU2014283319B2 (en)
BR (1) BR112015031835B1 (en)
CA (1) CA2915811C (en)
CL (1) CL2015003679A1 (en)
DK (1) DK3010543T3 (en)
HK (1) HK1223014A1 (en)
IL (1) IL243192B (en)
MX (1) MX366353B (en)
PT (1) PT3010543T (en)
RU (1) RU2685502C2 (en)
SG (1) SG11201510451RA (en)
WO (1) WO2014202646A1 (en)
ZA (1) ZA201600312B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (en) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc VESICULAR MONOAMINE CARRIER DIMETHOXYPHENYL INHIBITORS 2
PT3684333T (en) * 2017-09-21 2025-05-08 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
MX2020003421A (en) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (en) * 1971-12-14 1973-02-15 Parke Davis & Co NEW AMINOALCANOLS AND PROCESS FOR PREPARING THEM
US20090137837A1 (en) * 2007-06-21 2009-05-28 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
CL2008002793A1 (en) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
US8197858B2 (en) * 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (en) 2011-03-01 2018-01-25 Фарнекст NEW COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP2796132B1 (en) 2011-03-01 2018-05-02 Pharnext Baclofen and acamprosate based therapy of neurological disorders

Also Published As

Publication number Publication date
EP3010543A1 (en) 2016-04-27
ZA201600312B (en) 2022-12-21
IL243192B (en) 2019-12-31
CA2915811C (en) 2021-08-31
BR112015031835B1 (en) 2022-12-13
IL243192A0 (en) 2016-02-29
JP6476174B2 (en) 2019-02-27
RU2016101152A (en) 2017-07-24
NZ715951A (en) 2021-03-26
US20160158167A1 (en) 2016-06-09
RU2685502C2 (en) 2019-04-19
US20180042869A1 (en) 2018-02-15
EP3010543B1 (en) 2025-11-05
MX2015018040A (en) 2016-08-03
AU2014283319A1 (en) 2016-02-11
US9789072B2 (en) 2017-10-17
SG11201510451RA (en) 2016-01-28
KR20160055121A (en) 2016-05-17
DK3010543T3 (en) 2025-12-01
WO2014202646A1 (en) 2014-12-24
KR102254542B1 (en) 2021-05-24
PT3010543T (en) 2025-11-28
JP2016522235A (en) 2016-07-28
CL2015003679A1 (en) 2016-09-02
HK1223014A1 (en) 2017-07-21
AU2014283319B2 (en) 2019-07-25
CN105658238A (en) 2016-06-08
BR112015031835A8 (en) 2019-12-31
CA2915811A1 (en) 2014-12-24
BR112015031835A2 (en) 2017-07-25
CN105658238B (en) 2019-07-12

Similar Documents

Publication Publication Date Title
CR20150628A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
BR112015020453A8 (en) "oral extended-release dosage forms of tofacitinib and use of tofacitinib
CL2018000318A1 (en) Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
NI201700101A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING N - (3, 5 - DIMETOXIPHENIL) - N'- (1-METHYLETHYL) - N - [3- (1-METHYL-1H-PIRAZOL-4-IL) QUINOXALINE-6-IL] ETHANE-1 , 2-DIAMINE
MX383686B (en) 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CONDITIONS RELATED TO SMN DEFICIENCY.
HRP20250119T1 (en) A kdm1a inhibitor and its use in therapy
NI201500142A (en) 3-ACETYLAMINO-1 (PHENYL-HETEROARIL-AMINOCARBONIL OR PHENYL-HETEROARYL-CARBONYLAMINE) DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
CL2015002733A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
ME02910B (en) TETRAHYDROPYRROLOTHIAZINVERBINDUNGEN
BR112015011036A2 (en) heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CO2018004857A2 (en) Dihydroimidazopirazinone derivatives used in cancer treatment
GT201500053A (en) PHARMACEUTICAL COMPOSITION COVERED WITH REGORAFENIB
HRP20171648T1 (en) SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS A GRELIN-O-ACYL-TRANSFERASE INHIBITOR
BR112015022972A2 (en) s-ketamine hydrochloride pharmaceutical composition
MX377410B (en) INTEGRIN RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
PE20151607A1 (en) ORGANIC COMPOUND FORMULATIONS
CL2017000845A1 (en) Lysine Gingipain Inhibitors
BR112014002674A2 (en) Substituted 3- (biphenyl-3-yl) -4-hydroxy-8-methoxy-1-azaspiro [4.5] dec-3-en-2-ones
CR20130693A (en) TYPICAL ORTALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
BR112015026967A8 (en) phenoxyethyl dihydro-1h-isoquinoline, its uses, and pharmaceutical composition
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
BR112015023878A2 (en) compound, pharmaceutical composition, and use of a compound
BR112017021583A2 (en) Methods for treating inflammatory disorders
MX366353B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders.

Legal Events

Date Code Title Description
FG Grant or registration